Pirfenidone is a clinically approved TGF-β inhibitor that can significantly reduce the stiffness of the ECM in pancreatic cancer mice, while increasing vascular perfusion in the tumor to improve drug delivery and delay tumor progression [80]. The gene discussed is TGFB1; the disease is neoplasm.